NovaBridge Biosciences (NBP) Accounts Payables (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Accounts Payables data on file, last reported at $16.8 million in Q4 2025.

• Accounts Payables for Q4 2025 came in at $16.8 million, up 123.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.8 million (up 123.35% YoY), and the FY2025 annual result was $16.8 million, up 123.35% from the prior year.
• Accounts Payables advanced to $16.8 million in Q4 2025 per NBP's latest filing, from $7.5 million in the prior quarter.
• Over five years, Accounts Payables peaked at $99.3 million in Q4 2022 and troughed at $7.5 million in Q4 2024.
• A 5-year average of $53.2 million and a median of $49.7 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 84.84% in 2024, then soared 123.35% in 2025.
• A 5-year view of Accounts Payables shows it stood at $92.8 million in 2021, then increased by 7.05% to $99.3 million in 2022, then tumbled by 49.99% to $49.7 million in 2023, then plunged by 84.84% to $7.5 million in 2024, then soared by 123.35% to $16.8 million in 2025.
• Business Quant data shows NBP's Accounts Payables at $16.8 million in Q4 2025, $7.5 million in Q4 2024, and $49.7 million in Q4 2023.